Patents by Inventor Christiane Neumann
Christiane Neumann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200325224Abstract: One aspect as reported herein is using a method comprising the step of immunizing an experimental animal, three times with primary cynomolgus PBLs, whereby the PBLs are optionally enriched for T cells without using primary human PBLs as immunogen and without using a denaturing agent for producing a human cynomolgus cross-reactive antibody specifically binding to human CD3 epsilon of SEQ ID NO: 02 and specifically binding to a polypeptide of SEQ ID NO: 01, wherein the human cynomolgus cross-reactive antibody specifically binds to human and cynomolgus T cells, activates human T cells and does not bind to the same epitope as the antibody OKT3, the antibody UCHT1 and/or antibody the SP34.Type: ApplicationFiled: January 23, 2020Publication date: October 15, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Georg Tiefenthaler, Ekkehard Moessner, Valeria Lifke, Josef Platzer, Sonja Offner, Christiane Neumann, Mirko Ritter
-
Publication number: 20200299385Abstract: One aspect as reported herein is using a method comprising the step of immunizing an experimental animal, three times with primary cynomolgus PBLs, whereby the PBLs are optionally enriched for T cells without using primary human PBLs as immunogen and without using a denaturing agent for producing a human cynomolgus cross-reactive antibody specifically binding to human CD3 epsilon of SEQ ID NO: 02 and specifically binding to a polypeptide of SEQ ID NO: 01, wherein the human cynomolgus cross-reactive antibody specifically binds to human and cynomolgus T cells, activates human T cells and does not bind to the same epitope as the antibody OKT3, the antibody UCHT1 and/or antibody the SP34.Type: ApplicationFiled: January 23, 2020Publication date: September 24, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Georg Tiefenthaler, Ekkehard Moessner, Valeria Lifke, Josef Platzer, Sonja Offner, Christiane Neumann, Mirko Ritter
-
Patent number: 10781258Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: September 18, 2018Date of Patent: September 22, 2020Assignee: Roche Glycart AGInventors: Marina Bacac, Thomas Hofer, Ralf Hosse, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
-
Patent number: 10781257Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: September 18, 2018Date of Patent: September 22, 2020Assignee: Roche Glyeart AGInventors: Marina Bacac, Thomas Hofer, Ralf Hosse, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
-
Patent number: 10766967Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: September 30, 2016Date of Patent: September 8, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christiane Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Publication number: 20200231673Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: February 24, 2020Publication date: July 23, 2020Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
-
Publication number: 20200172633Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: August 15, 2019Publication date: June 4, 2020Inventors: Christian KLEIN, Ekkehard MOESSNER, Ralf HOSSE, Peter BRUENKER, Pablo UMANA, Christiane NEUMANN
-
Patent number: 10611840Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: January 24, 2018Date of Patent: April 7, 2020Assignee: Hoffman-La Roche Inc.Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Patent number: 10611841Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: January 24, 2018Date of Patent: April 7, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Patent number: 10323099Abstract: Multispecific antibodies based on antibodies that share a common light chain are described herein. The multispecific antibodies include: modified heavy chains having, by domain exchange, a common light chain variable domain VL; and two modified light chains having, by domain exchange, variable heavy chain domains of a first antibody (VH1) and a second antibody (VH2), wherein one light chain is of kappa isotype and one light chain is of lambda isotype. The present invention also relates to methods for the manufacture of such antibodies and their use.Type: GrantFiled: April 7, 2016Date of Patent: June 18, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Wolfgang Schaefer
-
Publication number: 20190002564Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: September 18, 2018Publication date: January 3, 2019Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Patent number: 10155815Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: February 24, 2014Date of Patent: December 18, 2018Assignee: Roche Glycart AGInventors: Marina Bacac, Thomas Hofer, Ralf Hosse, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
-
Publication number: 20180282410Abstract: The present invention generally relates to bispecific antigen binding molecules for activating T cells, more particularly bispecific antigen binding molecules for activating T cells targeting the Robo 4 receptor. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. In addition, the invention also relates to antibodies that specifically bind to Robo 4.Type: ApplicationFiled: September 29, 2016Publication date: October 4, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Oliver AST, Marina BACAC, Sabine BAUER, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Samuel MOSER, Christiane NEUMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMAÑA, Tina WEINZIERL
-
Patent number: 10087250Abstract: The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: October 3, 2013Date of Patent: October 2, 2018Assignee: Roche Glycart AGInventors: Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Pablo Umaña
-
Publication number: 20180273643Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: March 12, 2018Publication date: September 27, 2018Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane Neumann, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
-
Publication number: 20180086849Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: July 20, 2017Publication date: March 29, 2018Inventors: Marina Bacac, Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
-
Publication number: 20170253670Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: May 19, 2017Publication date: September 7, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Christian Klein, Ekkehard Moessner, Ralf Hosse, Peter Bruenker, Pablo Umana, Christiane Neumann
-
Publication number: 20170233475Abstract: One aspect as reported herein is using a method comprising the step of immunizing an experimental animal, three times with primary cynomolgus PBLs, whereby the PBLs are optionally enriched for T cells without using primary human PBLs as immunogen and without using a denaturing agent for producing a human cynomolgus cross-reactive antibody specifically binding to human CD3 epsilon of SEQ ID NO: 02 and specifically binding to a polypeptide of SEQ ID NO: 01, wherein the human cynomolgus cross-reactive antibody specifically binds to human and cynomolgus T cells, activates human T cells and does not bind to the same epitope as the antibody OKT3, the antibody UCHT1 and/or antibody the SP34.Type: ApplicationFiled: November 22, 2016Publication date: August 17, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Georg Tiefenthaler, Ekkehard Moessner, Valeria Lifke, Josef Platzer, Sonja Offner, Christiane Neumann, Mirko Ritter
-
Publication number: 20170198043Abstract: The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: October 20, 2016Publication date: July 13, 2017Applicant: Roche Glycart AGInventors: Johannes Auer, Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Wolfgang Schaefer, Claudio Sustmann, Pablo Umana
-
Patent number: 9689408Abstract: A method for bistably actuating an actuator includes applying positive pressure in an actuator fluid supply that is fluidly connected to an actuator chamber by means of an actuator fluid supply connection, wherein a working positive pressure is generated in the actuator chamber, whereby an actuator element fluidly connected to the actuator chamber is brought from a resting position to an actuation position, pressure-tight sealing of the actuator fluid supply connection, so that the working positive pressure in the actuator chamber is maintained and the actuator element remains in the actuation position.Type: GrantFiled: January 31, 2013Date of Patent: June 27, 2017Assignee: Karlsruher Institut für TechnologieInventors: Bastian Rapp, Christiane Neumann, Elisabeth Wilhelm, Achim Voigt